# Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke

> **NCT04891497** · PHASE2 · WITHDRAWN · sponsor: **Xuanwu Hospital, Beijing**

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Dimethyl Fumarate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04891497
- **Lead sponsor:** Xuanwu Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** There are no suitable patients
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891497, "Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04891497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*